NextCure to Host and Webcast Event at the 2019 Society for Immunotherapy of Cancer (SITC) Annual Meeting
05 November 2019 - 12:05AM
NextCure, Inc., a clinical-stage biopharmaceutical company
committed to discovering and developing next-generation
immunomedicines for cancer and other immune-related diseases, today
announced that the company will host and webcast an event with its
Chief Medical Officer at the 34th Annual Meeting of the Society for
Immunotherapy of Cancer (SITC) on Saturday, November 9, 2019 at
6:30 p.m. Eastern Time at the Gaylord National Hotel &
Convention Center in National Harbor, Maryland. At the event,
NextCure will discuss updated clinical results from the Phase 1
portion of its ongoing trial with NC318 that are being presented
earlier in the day at SITC.
Institutional investors and analysts are requested to rsvp to
Drew Phillips at drew.phillips@westwicke.com or by phone at
443-213-0497.
To access the live webcast and subsequent archived recording of
this and other company presentations, please visit the investor
section of NextCure's website at www.nextcure.com. The archived
webcast will remain available for replay on NextCure’s website for
90 days.
About NextCure, Inc.
NextCure is a clinical-stage biopharmaceutical company committed
to discovering and developing novel, first-in-class immunomedicines
to treat cancer and other immune-related diseases. Through our
proprietary FIND-IO™ platform, we study various immune cells to
discover and understand targets and structural components of immune
cells and their functional impact in order to develop
immunomedicines. Our initial focus is to bring hope and new
treatments to patients who do not respond to current cancer
therapies, patients whose cancer progresses despite treatment and
patients with cancer types not adequately addressed by available
therapies. For more information, please visit www.nextcure.com.
Cautionary Statement Regarding Forward-Looking
Statements
This press release contains forward-looking statements,
including statements pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
are based on current expectations, forecasts, assumptions and other
information available to NextCure as of the date hereof.
Forward-looking statements include statements regarding NextCure’s
expectations, beliefs, intentions or strategies regarding the
future and can be identified by forward-looking words such as
“may,” “will,” “potential,” “expects,” “believes,” “intends,”
“hope,” “towards,” “forward,” “later,” “on track” and similar
expressions. Examples of forward-looking statements in this press
release include, among others, statements about the sufficiency of
NextCure’s cash and cash equivalents, the use of proceeds from
NextCure’s recent initial public offering, the pace and expected
timing of NextCure’s ongoing clinical study of NC318 and its other
research and development programs, and NextCure’s plans, objectives
and intentions with respect to the discovery and development of
immunomedicines. Forward-looking statements involve substantial
risks and uncertainties that could cause actual results to differ
materially from those projected in any forward-looking statement.
Such risks and uncertainties include, among others: NextCure’s
limited operating history and no products approved for commercial
sale; NextCure’s history of significant losses; NextCure’s need to
obtain additional financing; risks related to clinical development,
marketing approval and commercialization; and the unproven approach
to the discovery and development of product candidates based on
NextCure’s FIND-IO platform. More detailed information on these and
additional factors that could affect NextCure’s actual results are
described in NextCure’s filings with the Securities and Exchange
Commission (the “SEC”), including NextCure’s Form 10-Q filed with
the SEC on August 12, 2019. You should not place undue reliance on
any forward-looking statements. Forward-looking statements speak
only as of the date of this press release, and NextCure assumes no
obligation to update any forward-looking statements, even if
expectations change.
Investor Inquiries
Timothy Mayer, Ph.D.
NextCure, Inc.
Chief Operating Officer
(240) 762-6486
IR@nextcure.com
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From Apr 2024 to May 2024
NextCure (NASDAQ:NXTC)
Historical Stock Chart
From May 2023 to May 2024